Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10971581 | 0.83 | CA1 (0.47) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10974482 | 0.83 | MEN1 (0.42) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2376287 | 0.83 | MEN1 (0.39) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL10867559 | 0.83 | CA2 (0.52) | GAACA1CA2CA12CYP2C9 | |
| SCHEMBL2024322 | 0.82 | CTSB (0.53) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL2043251 | 0.80 | MEN1 (0.42) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL647187 | 0.78 | MEN1 (0.41) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL3412099 | 0.78 | MEN1 (0.44) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL31532437 | 0.78 | LOX (0.41) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 | |
| SCHEMBL507714 | 0.78 | LOX (0.41) | MEN1CYP1A2CYP3A4CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866277-B1 | SULFONYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY INC (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8450373-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2511257-A2 | Alpha ketoamide compounds as cysteine protease inhibitors | ViroBay, Inc. (US) | 2012-10-17 | — | — | EP | disclosed |
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | APPLERA CORPORATION (US) | 2012-07-26 | — | — | US | disclosed |
| US-8013183-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-7696250-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | VIROBAY, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-7488848-B2 | Alpha ketoamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2008-11-20 | — | — | US | disclosed |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORPORATION (US) | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190714-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | MEN1 4435/4885CYP1A2 2477/4885CYP3A4 2066/4885 |
| US-20080287446-A1 | Sulfonyl Containing Compounds as Cysteine Protease Inhibitors | CTSS, CTSF, CTSB | MEN1 4158/4885CYP1A2 3666/4885CYP3A4 1884/4885 |
| US-20090170909-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | MEN1 4435/4885CYP1A2 2477/4885CYP3A4 2066/4885 |
| US-20070021353-A1 | Alpha ketoamide compounds as cysteine protease inhibitors | CTSS, CTSF, CTSB | MEN1 4435/4885CYP1A2 2477/4885CYP3A4 2066/4885 |
| US-20100305331-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CTSS, CTSF, CTSB | MEN1 4435/4885CYP1A2 2477/4885CYP3A4 2066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.